UMA
14.12.2021 11:02:09 CET | Business Wire | Press release
Jabra and UMA have partnered to deliver innovative video conferencing and meeting room solutions, enabling Jabra devices to be managed seamlessly from one place on the UMA dashboard with real-time analytics. With Jabra PanaCast intelligent video conferencing cameras, users can manage meeting room occupancy levels and control room occupancy levels from a desktop, smartphone or meeting room display panel to optimise the use of office space.
The Jabra PanaCast and PanaCast 50’s unique 180-degree field-of-view covers the whole room and generates anonymous room occupancy data. This feeds real-time information into the UMA dashboard, providing insights and analytics. UMA automatically makes a meeting room available to book in the event of a no-show. Rooms can also be auto-booked by simply walking in.
With the shift towards hybrid-working, companies are reviewing their technology investments and office space-utilisation. UMA enables users to manage meeting-room and desk utilisation and device management of audio-visual devices, all from a single pane of glass. Organisations are now able to optimise their facilities and technology infrastructure to create an efficient and safe workplace, compliant with Covid Winter-Plan guidelines.
The combined value-proposition of UMA and Jabra allows customers to realise an improved return on their technology investments through business intelligence and simpler mechanisms to support and maintain their meeting room technology. Users can check Jabra device status, remotely diagnose and fix issues, and push software updates.
Nigel Dunn, Managing Director, EMEA North at Jabra says, “We are thrilled to be teaming up with UMA to deliver a new standard in meeting room solutions for hybrid working. Jabra PanaCast’s data-driven insights and analytics gives a real-time view of how the workplace is being used, enabling companies to improve efficiency and maximise their real estate. It’s now time to start thinking about future-proofing offices and taking conferencing and the meeting booking experience to the next level.”
Nathan Rogers, Head of Channel, UMA says, “I’m looking forward to continuing to build a strong partnership with Jabra. The UMA and Jabra integration will deliver meaningful insights to businesses ensuring they understand how their real estate is being used. UMA delivers a simplified user experience to enable the booking of meeting spaces, and when partnered with the Jabra PanaCast the business has enhanced analytical data at their fingertips. Jabra’s audio experience and smart UC technology working in coalition with our Workplace Software will deliver a game changing advantage to users.”
Working in partnership with our mutual UK and European distributors means the reseller and Integrator customers will get a cohesive approach.”
The Jabra PanaCast is supported on UMA’s platform today, with PanaCast 50 to follow in early 2022.
For more information, please visit: https://www.jabra.co.uk/Business/for-your-platform/uma
About Jabra
Jabra is a world leading brand in audio, video, and collaboration solutions – engineered to empower consumers and businesses. Proudly part of the GN Group, we are committed to letting people hear more, do more, and be more than they ever thought possible. Jabra engineering excellence leads the way, building on 150 years of pioneering work within the GN Group.
This allows us to create integrated tools for contact centres, offices, and collaboration that help professionals work more productively from anywhere; and true wireless headphones and earbuds that let consumers better enjoy calls, music, and media. The GN Group, founded in 1869, operates in 100 countries and delivers innovation, reliability, and ease of use. GN employs 6,500 people and in 2020 reported annual revenue of DKK 13.4bn. The Jabra brand accounts for approx. DKK 8.7bn and employs 1,900 people. GN makes life sound better and is Nasdaq Copenhagen listed. www.jabra.com
About UMA
UMA is an innovative workplace software-as-a-service platform, connecting internet-of-things, audio, video, and collaboration technology and digitising the workplace environment.
Driven by a passion to improve technology user experiences in the workplace UMA enables you to book and manage resources and optimise space and environmental conditions, adapting to the changing needs of the workforce.
UMA was founded in Halifax, Yorkshire, UK and delivers solutions to enterprise and SME customers from all industry verticals across the world.
Find out more and get started with a free trial of UMA at www.askuma.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
